Editorial

January 18, 2016

Dear ESMINT friends,

We are happy to invite you to the 8th ESMINT Congress in Nice.

After the historical breakthrough with the positive thrombectomy trials last year, we need to get back to business. This must not mean to business as usual. We are encountering substantial developments representing both significant challenges and great opportunities at the same time.

First, numbers of neurointerventions have increased enormously. Educating and training young Neurointerventionalists is a fundamental challenge while keeping up with the increasing workload. This congress will devote considerable time to education and training. In particular, a newly introduced interactive case discussion format for younger colleagues will demonstrate the abundance of different opinions and technical possibilities to solve a particular clinical problem. A session dedicated to teaching strategies of neurointerventions enables discussion about future directions in training and education. Another session will cover the latest developments in the imaging of interventions.

Second, the importance of Neurointerventionalists as members of the interdisciplinary neuro-team has further increased. ESMINT needs to describe standardized processes, write guidelines and implement quality controls. As a leading professional society, ESMINT plays a crucial role in development of S3 (evidence based)-guidelines for the implementation of thrombectomy in clinical practice in Europe. There will be joint sessions with European Association of Neurosurgical Societies (EANS) section of Vascular Neurosurgery and European Stroke Organization (ESO) to foster further collaboration of the societies. As key players in the neurointerventional services, the nursing staff will have a dedicated satellite symposium for continuous education and discussions.

Third, interventional technology is advancing with ever-increasing speed. In Europe, we are at the forefront of this development. Last year’s “New Technology Industry Symposium” was a great success and will be further developed this year. However, we need to make sure that modifications in technology are translated into real clinical benefit for our patients. To support this development, we will include a new format “Best European studies” where both design and results of clinical studies initiated by Neurointerventionalists will be discussed.

Membership in the ESMINT community offers unique chances to further support and simplify collaborations across country borders in Europe.

Jens Fiehler
President of the 8th ESMINT Congress